TABLE 5.

Ongoing clinical trials.

NCT number	Institution	Study phase/design	Starting date–estimated primary completion date	Estimated number of enrolled patients	Study arms	Outcome measures (time frame)
NCT03687723 (41)	Hannover Medical School, Hannover, Germany	Multicenter, observational	October 2016–December 2021	60	Clinical use of OCS	Primary outcome: patient survival (12 months); secondary outcomes: patient and graft survival (30 days)
NCT03991923 (42)	UZ Leuven, Leuven, Flemish Brabant, Belgium, etc., total eight centers in Europe	Multicenter, randomized	July 2020–July 2021	202	NIHP, STS	Primary outcome: mortality and graft dysfunction (30 days); secondary outcomes: mortality and graft dysfunction (time frame 12 months)
NCT04066127 (43)	Skane University Hospital Lund, Skane, Sweden	Randomized	June 2020–December 2022	66	NIHP, STS	Primary outcome: survival free of acute cellular rejection and re-transplantation (12 months); secondary outcomes: I/R-tissue injury, early allograft dysfunction, and health status
NCT03835754 (44)	Cedars-Sinai, Stanford University, Yale New Haven Hospital, etc., total 12 centers from United States	Multicenter	June 2019–November 2020	48	Clinical use of OCS, high risk donors	Primary outcome: patient survival (30 days), absence of severe PGD (24 h post heart transplant); secondary outcome: patient and graft survival (30 days), incidence of severe PGD and donor heart utilization rate (24 h post-transplant)
NCT03831048 (45)	Stanford University, Yale New Haven Hospital, Mayo Clinic, etc., total 16 centers from United States	Multicenter, randomized	December 2019–August 2021	212	DCD donors: OCS, SCS	Primary outcome: survival (6 months); secondary outcome: utilization rate (within 24 h post-transplant)

DCD, donation after circulatory death; NIHP, non-ischemic hypothermic preservation; OCS, organ care system; PGD, primary graft dysfunction; SCS, static cold storage.